| # | Drug | Count |
|---|---|---|
| 0 | DOCETAXEL | 15 |
| 1 | DOCETAXEL ANHYDROUS | 15 |
| 2 | CARBOPLATIN | 12 |
| 3 | LETROZOLE | 11 |
| 4 | AFATINIB | 10 |
| 5 | BEVACIZUMAB | 10 |
| 6 | CYCLOPHOSPHAMIDE | 10 |
| 7 | CYCLOPHOSPHAMIDE FOR INJECTION | 10 |
| 8 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 10 |
| 9 | FULVESTRANT | 9 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | L DOPA | 2 | 0.0075 |
| 1 | DACOMITINIB | 3 | 0.0040 |
| 2 | AFATINIB | 10 | 0.0015 |
| 3 | INAVOLISIB | 1 | 0.0015 |
| 4 | DACARBAZINE | 4 | 0.0005 |
| 5 | GRANULOCYTE COLONY STIMULATING FACTOR | 1 | 0.0005 |
| 6 | BRINZOLAMIDE | 3 | 0.0003 |
| 7 | ERLOTINIB HYDROCHLORIDE | 4 | 0.0003 |
| 8 | GADODIAMIDE | 1 | 0.0003 |
| 9 | VALSARTAN AND HYDROCHLOROTHIAZIDE | 4 | 0.0003 |
| # | Drug class | Count |
|---|---|---|
| 0 | Kinase Inhibitor [EPC] | 28 |
| 1 | Aromatase Inhibitor [EPC] | 20 |
| 2 | Microtubule Inhibitor [EPC] | 18 |
| 3 | Platinum-based Drug [EPC] | 16 |
| 4 | Alkylating Drug [EPC] | 11 |
| 5 | Folate Analog Metabolic Inhibitor [EPC] | 11 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 11 |
| 7 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 10 |
| 8 | Estrogen Receptor Antagonist [EPC] | 9 |
| 9 | Corticosteroid [EPC] | 6 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Guanylate Cyclase-C Agonist [EPC] | 1 | 0.0005 |
| 1 | Estrogen Receptor Antagonist [EPC] | 9 | 0.0002 |
| 2 | Paramagnetic Contrast Agent [EPC] | 1 | 0.0002 |
| 3 | Aromatase Inhibitor [EPC] | 20 | 0.0002 |
| 4 | Phosphodiesterase 3 Inhibitor [EPC] | 1 | 0.0002 |
| 5 | Carbonic Anhydrase Inhibitor [EPC] | 3 | 0.0001 |
| 6 | Microtubule Inhibitor [EPC] | 18 | 0.0001 |
| 7 | Interleukin-17A Antagonist [EPC] | 4 | 0.0001 |
| 8 | Prostacyclin Receptor Agonist [EPC] | 2 | 0.0001 |
| 9 | Provitamin D2 Compound [EPC] | 2 | 0.0001 |